5 Healthcare Stocks Billionaires Are Loading Up On

4. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Billionaire Investors: 18
Number of Hedge Fund Holders: 57

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is an American medical research and drug development company that also specializes in genetic medicine. In May, RBC Capital boosted its price target on the stock to $218 with an Outperform rating on the shares, presenting a positive stance on the company’s outlook.

In the first quarter of 2023, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported revenue of $253.5 million, which showed a 20.3% growth from the same period last year. At the end of March 2023, it had over $871.6 million in cash and cash equivalents.

As of the close of the March quarter, 57 hedge funds in Insider Monkey’s database owned stakes in Sarepta Therapeutics, Inc. (NASDAQ:SRPT), with a collective value of over $2.4 billion. Billionaire Thomas Steyer’s Farallon Capital was one of the company’s leading stakeholders in Q1.